samedan logo
 
 
 
spacer
home > ebr > spring 2020 > eschewing the escalation of salaries as safety professionals grow scarcer
PUBLICATIONS
European Biopharmaceutical Review

Eschewing the Escalation of Salaries as Safety Professionals Grow Scarcer

How to retain relevant, experienced safety and regulatory talent has arguably never been higher up the list of conversation topics in life sciences than it is today, as younger professionals’ ambitions for a broad base of experience conflict with firms’ needs to hang onto the expertise they have invested in. The challenge appears to be a global one too, judging by the wide spectrum of comments at the FT Global Pharmaceutical and Biotechnology Conference in London last November. There, attendees from both sides of the Atlantic gave voice to their concerns and swapped ideas for combatting the talent shortfall and the risk of skilled practitioners moving on to seemingly greener pastures.

Biotech companies are disproportionately vulnerable, unable to match the salaries and ‘on-paper’ benefits of the global pharma giants. Too often, these more modest-sized organisations provide new graduates with a firm foundation in pharmacovigilance (PV), only for a larger brand to poach them – wooing them with a more senior version of the same role and a 20% hike in salary.

Money Isn’t Everything

There is a growing realisation among life science employers that they must come up with new and creative ways to foster and hold on to rising talent to stay competitive. Whatever the care needed when generalising about ‘millennials’ as a single category of employee, it is clear that there has been a shift in values among those in the earlier stages of their working life. As well as being hungry for a greater range of career experiences, for example, newer graduates are reputedly less influenced by salary than previous generations. Freedom to explore, create, innovate, and experiment at work are often among their personal priorities, along with the ability to protect their work-life balance, which may mean being able to apply for extended periods off work to fulfil extracurricular ambitions, work from home, or have more control over their working hours.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Alan White is CEO at Arriello, a specialist global provider of innovative, high-impact market access, regulatory affairs, and pharmacovigilance solutions and services for pharma and biotech firms primarily in Europe and North America.
spacer
Alan White
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Myonex Opens New Global Headquarters

Myonex, a leading global clinical trial supply company, marked the opening of its new global headquarters and US operational facility with a ribbon-cutting ceremony on the company’s 14-acre campus.
More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

Aigenpulse

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 
Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement